Journal
CURRENT GENE THERAPY
Volume 9, Issue 5, Pages 396-408Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156652309789753338
Keywords
-
Categories
Funding
- Leukemia and Lymphoma Society Specialized Center of Research [7018]
- NIH [PO1CA94237, P50CA126752]
- Leukemia and Lymphoma Society Translational Research
- Doris Duke Charitable Foundation/Clinical Scientist development
- ASBMT New Investigator
- When Everyone Survives
- NATIONAL CANCER INSTITUTE [P50CA126752, P01CA094237] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Adoptive T cell therapies can produce objective clinical responses in patients with hematologic and solid malignancies. Genetic manipulation of T lymphocytes has been proposed as a means of increasing the potency and range of this anti-tumor activity. We now review how coupling expression of transgenic receptors with countermeasures against potent tumor immune evasion strategies is proving highly effective in pre-clinical models and describe how these approaches are being evaluated in human subjects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available